Myomo (MYO) Short term Debt (2017 - 2025)

Myomo (MYO) reported Short term Debt of $2.7 million for Q4 2025, up 368.56% quarter-over-quarter from $583333.0 in Q3 2025.

Myomo (MYO) Short term Debt (2017 - 2025) Analysis & Trends

Myomo has reported Short term Debt for 5 years, with the latest figure at $2.7 million in Q4 2025.

For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Dec 2025 stood at $2.7 million (changed N/A YoY), and the FY2025 full-year result was $2.7 million, changed N/A from the prior year.
Short term Debt for Q4 2025 stood at $2.7 million, up from $583333.0 in the prior quarter.
The five-year high for Short term Debt was $2.7 million in Q4 2025, with the low at $583333.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn
10	Myomo	45.01 Mn	26.62 Mn	-

Download Data